



# Novel Coronavirus Characteristic Cerebrovasculopathic Effects

Sara Zandpazandi<sup>1</sup>, Mohamad Reza Shahmohammadi<sup>1\*</sup>

<sup>1</sup>Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

\*Correspondence to Mohamad Reza Shahmohammadi, Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: dr\_mr11@yahoo.com

Published online 28 September, 2020



## Dear Editor,

Coronavirus beta 2 started infecting people from china in fall 2019. It did not take a long time to spread worldwide and take many victims and cause many deaths.

As it is known, beta coronaviruses (SARS-Cov-2), which cause the severe acute respiratory syndrome, COVID-19 pandemic, have developed neurological manifestations in addition to primary respiratory symptoms in a significant number of patients.<sup>1,2</sup> The occurrence of anosmia and hyposmia is evidence of this claim.

Stroke incidence of 0.9%-2% in especially young COVID-19 patients, is reported.<sup>2-5</sup> The worst issue about this incidence is the high mortality rate despite even optimal treatment.<sup>6,7</sup> Since the number of patients is as much as the World Health Organization (WHO) could declare the disease pandemic, it is important to review the pathophysiology in order to estimate the risk and guide the decision making. This letter aims to review the mechanism of virus pathophysiology and the following cerebrovascular presentations reported until now.

SARS- CoV-2 virus blocks the angiotensinogen-converting enzyme 2 (ACE2), which plays a critical role in the autoregulation of cerebral perfusion. It has also reported that it induces a hypercoagulable state (same as other flu viruses but with more mortality) and a hyperinflammatory response with cytokine storm characterization.<sup>8,9</sup> Inhibiting ACE2, neuroinvasion, and neurovirulation, and hypercoagulopathy induction are the pathophysiologic characteristics of the COVID-19.<sup>10-16</sup>

In some patients, the cerebrovascular attack was noticed as the early manifestation with no severe presentations. The vascular occlusion had seen in both arterial and venous sides; most of them occurred in large vessels. There are unusual manifestations reported in recent studies that there are young patients without previous history or risk factors, represented acute ischemic stroke, sinus thrombosis, tandem occlusion (internal carotid artery and middle cerebral artery M1 occlusion), carotid

T occlusions, M1 and A2 occlusion, central retinal artery occlusion.<sup>17</sup>

The mean age of the patients was lower than historical non-COVID stroke patients. There was a noticeable number of patients who presented the cerebrovascular stroke as the early manifestation of COVID-19. There is a report of a 9-day lag period between the COVID-19 symptoms and the cerebrovascular event occurrence.<sup>16</sup> There are a few interpretations for the mechanism of COVID-19 vasculopathy incidence: epitheliopathy, i.e., a direct vasculopathic effect, immune-mediated platelet activation, potentiation of prothrombic surrounding, cardiac arrhythmias caused by infection, and also dehydration.<sup>12-15,18</sup>

It is vital in pandemic break-outs to raise awareness to improve decision-making, risk estimation, and health care workers' protection. We should watch patients and novel manifestations precisely and report the new findings orderly for this issue.

## Conflict of Interest

The authors declare that they have no conflict of interests.

## Ethical Statement

Not applicable.

## References

1. Padovani A. Special Report COVID-19: Neurologists Adapt in Northern Italy. 2020. Available From: <https://www.eanpages.org/2020/04/01/specialreport-covid-19-neurologists-adapt-in-northern-italy/>. Accessed April 9, 2020.
2. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol.* 2020;77(6):683-90. doi: 10.1001/jamaneurol.2020.1127.
3. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. *ACS Chem Neurosci.* 2020;11(7):995-8. doi: 10.1021/acscchemneuro.0c00122.

4. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun*. 2020;87:18-22. doi: 10.1016/j.bbi.2020.03.031.
5. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and stroke in a New York healthcare system. *Stroke*. 2020;51(7):2002-11. doi: 10.1161/strokeaha.120.030335.
6. Wang A, Mandigo GK, Yim PD, Meyers PM, Lavine SD. Stroke and mechanical thrombectomy in patients with COVID-19: technical observations and patient characteristics. *J Neurointerv Surg*. 2020;12(7):648-53. doi: 10.1136/neurintsurg-2020-016220.
7. Aggarwal G, Lippi G, Michael Henry B. Cerebrovascular disease is associated with an increased disease severity in patients with coronavirus disease 2019 (COVID-19): a pooled analysis of published literature. *Int J Stroke*. 2020;15(4):385-9. doi: 10.1177/1747493020921664.
8. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. 2020;46(4):586-90. doi: 10.1007/s00134-020-05985-9.
9. Xu P, Sriramula S, Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. *Am J Physiol Regul Integr Comp Physiol*. 2011;300(4):R804-17. doi: 10.1152/ajpregu.00222.2010.
10. Urbanek C, Palm F, Grau AJ. Influenza and stroke risk: a key target not to be missed? *Infect Disord Drug Targets*. 2010;10(2):122-31. doi: 10.2174/187152610790963474.
11. Toschke AM, Heuschmann PU, Wood O, Wolfe CD. Temporal relationship between influenza infections and subsequent first-ever stroke incidence. *Age Ageing*. 2009;38(1):100-3. doi: 10.1093/ageing/afn232
12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-4. doi: 10.1016/s0140-6736(20)30628-0.
13. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. *J Thromb Haemost*. 2020;18(7):1559-61. doi: 10.1111/jth.14849.
14. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. *N Engl J Med*. 2020;382(17):e38. doi: 10.1056/NEJMc2007575.
15. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417-8. doi: 10.1016/s0140-6736(20)30937-5.
16. Sweid A, Hammoud B, Bekelis K, Missios S, Tjoumakaris SI, Gooch MR, et al. Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. *Int J Stroke*. 2020:1747493020937189. doi: 10.1177/1747493020937189.
17. Sweid A, Hammoud B, Weinberg JH, Oneissi M, Raz E, Shapiro M, et al. Letter: thrombotic neurovascular disease in COVID-19 patients. *Neurosurgery*. 2020;87(3):E400-e6. doi: 10.1093/neuros/nyaa254.
18. Ntaios G, Michel P, Georgiopoulou G, Guo Y, Li W, Xiong J, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. *Stroke*. 2020;51(9):e254-e8. doi: 10.1161/strokeaha.120.031208.

**Citation:** Zandpazandi S, Shahmohammadi MR. Novel Coronavirus Characteristic Cerebrovasculopathic Effects. *Clin Neurosci J*. 2020;7(4):162-163. doi:10.34172/icnj.2020.19.